4 results
The general objectives are to assess the safety of combining dasatinib with CCNU as well as to assess activity of this combination and CCNU alone in GBM patients who have relapsed after prior treatment with temozolomide and radiotherapy
To compare the best confirmed complete cytogenetic response (CCyR) rates within 12 months in newly diagnosed chronic phase CML subjects treated with dasatinib versus imatinib
To evaluate if an individualized antithrombotic P2Y12-inhibitor monotherapy in comparison to an individualized DAPT treatment is superior regarding bleeding events and non-inferior regarding ischemic events in patient with CCS after PCI.
To examine the effect of oral dasatinib plus quercetin on liver fibrosis as assessed by histology in individuals with biopsy-proven NAFLD with fibrosis by performing a double*blind randomized controlled proof*of*principle study. The primary endpoint…